Drosophila, as the test organism, was used to assess 17 chemicals. The teratogenic potential of 15 of these chemicals is well established from animal studies or human epidemiology. The test involves examination of adult flies following treatment during larval stages of development. Flies are examined for abnormal external morphology. The incidence of abnormalities in treated and control populations is compared using the Chi-square test. All 17 chemicals were active to varying degrees in the test system. Most chemicals produced a unique response yielding individual patterns of abnormalities. These results suggest that Drosophila may have the potential to become a valuable teratogen screen, but further, more rigorous examination–particularly with nonteratogens–is required.
References
1.
1. Wilson, J.G. (1978). Review of in vitro systems with potential for use in teratogenicity screening. J. Environ. Pathol. Toxicol.2, 149–167.
2.
2. Baars, A.J., Zijlstra, J.A., Vogel, E., and Breimer, D.D. (1977). The occurrence of cytochrome P-450 and aryl hydrocarbon hydroxylase activity in Drosophilia melanogaster, and the importance of this metabolizing capacity for the screening of carcinogenic and mutagenic properties of foreign compounds. Mutation Res.44, 257–268.
3.
3. Clayton, F.C., and Francoeur, R.T. (1971). Some teratogenic effects of vinblastine on the external morphology of Drosophila melanogaster.Oncology25, 188–192.
4.
4. Gilbert, E.F., Pitot, H.C., Bruyere, H.J., and Cheung, A.L. (1973). Teratogenic effects of 5-bromodeoxyuridine on the external morphology of Drosophila melanogaster.Teratology7, 205–208.
5.
5. Parkash, O. (1971). On the teratogenic effect of thymidine and its suppression by deoxycytidine in Drosophila melanogaster.Experientia27, 1089–1090.
6.
6. Schardein, J.L. (1976). Drugs as Teratogens. Cleveland, OH: CRC press, 291 pp.
7.
7. Schuler, R.L., Hardin, B.D., and Niemeier, R.W. (1982). Drosophila as a tool for the rapid assessment of chemicals for teratogenicity. Terat. Carcin. Mut.2, 293–301.
8.
8. Wurgler, F.E., Lezzi, M., and Graf, W. (1971). A device for easily anesthetizing large numbers of flies. Drosophila Inform. Serv.46, 149.
9.
9. Poulson, D.F. (1965). Histogenesis, organogenesis, and differentiation in the embryo of Drosophila melanogaster. In: Biology of Drosophila. M. Demerec (ed.). Hafner Publishing Co., pp. 238–241.
10.
10. Ferreira, N.R., and Frota-Pessoa, D. (1969). Trisomy after colchicine therapy. Lancet1, 1160–1161.
11.
11. Karnofsky, D.A. (1965). Mechanisms of action of certain growth-inhibiting drugs. In: Teratology: Principles and Techniques. J.G. Wilson and J. Warkany. (eds.). Chicago: University of Chicago Press, pp. 185–213.
12.
12. Federal Register. Vol. 49., No. 227, Friday, November 23, 1984, pp. 46324–46331.
13.
13. Smith, M.K., Kimmel, G.L., Kochhar, D.M., Shepard, T.H., Spielberg, S.P., and Wilson, J.G. (1983). A selection of candidate compounds for in vitro teratogenesis test validation. Terat. Carcin. Mut.3(6), 461–480.
14.
14. Johnson, E.M. (1980). A subvertebrate system for rapid determination of potential teratogenic hazards. J. Environ. Pathol. Toxicol.4, 153–156.
15.
15. Biddle, F.G. (1978). Use of dose-response relationships to discriminate between the mechanisms of cleft palate induction by different teratogens: An argument for discussion. Teratology18, 247–252.
16.
16. Chamberlain, J.G. (1966). Development of cleft palate induced by 6-aminonicotinamide late in rat gestation. Anat. Rec.156, 31–40.
17.
17. Schardein, J.L., Woolsey, E.T., Peltzer, M.A., and Kaump, D.H. (1967). Congenital malformations induced by 6-aminonicotinamide in rabbit kits. Exp. Mol. Pathol.6, 335–346.
18.
18. Turbow, M.M., Clark, W.H., and Dipaolo. J.A. (1971). Embryonic abnormalities in hamsters following intrauterine injection of 6-aminonicotinamide. Teratology4, 427–432.
19.
19. Courtney, K.D., and Valerio, D.A. (1968). Teratology in the Macaca mulatta. Teratology1, 163–172.
20.
20. Nishimura, H., and Nakai, K. (1960). Congenital malformations in offspring of mice treated with caffeine. Proc. Soc. Exp. Biol. Med.104, 140–142.
21.
21. Collins, T.F.X., Welsh, J.J., Black, T.N., and Colline, E.V. (1981). Study of the teratogenic potential of caffeine given by oral intubation to rats. Regul. Toxicol. Pharmacol.1, 355–378.
22.
22. Fujii, T., and Nishimura, H. (1972). Adverse effects of prolonged administration of caffeine on rat fetus. Toxicol. Appl. Pharmacol.22, 449–457.
23.
23. Bertrand, M., Giroud, J., and Rigaud, M.F. (1970). Ectrodachtylie provoquee par la cafeine chez les rongeurs. Role des facteurs specifiques et genetiques. CR Soc. Biol. (Paris)164, 1488–1489.
24.
24. Sadler, T.W., and Kochhar, D.M. (1975). Teratogenic effects of chlorambucil on in vivo and in vitro organogenesis in mice. Teratology12, 71–78.
25.
25. Chaube, S., and Murphy, M.L. (1968). The teratogenic effects of the recent drugs in cancer chemotherapy. In: Advances in Teratology. D.H.M. Woollam. (ed.). Vol. III, pp. 20–205.
26.
26. Monie, I.W. (1961). Chlorambucil-induced abnormalities of the urogential system of rat fetuses. Anat. Rec.139, 145–153.
27.
27. Shotton, D, and Monie, I.W. (1963). Possible teratogenic effect of chlorambucil on a human fetus. JAMA186, 74–75.
28.
28. Didock, K., Jackson, D., and Robson, J.M. (1965). The action of some nucleotoxic substances of pregnancy. Br. J. Pharmacol.11, 437–441.
29.
29. Gibson, J.E., and Becker, B.A. (1968). Teratogenicity of cyclophosphamide in mice. Cancer Res.28, 475–480.
30.
30. Chaube, S., Kury, G., and Murphy, M.L. (1967). Teratogenic effects of cyclophosphamide in the rat. Cancer Chemother. Rep.51, 363–376.
31.
31. Fritz, H., and Hess, R. (1971). Effects of cyclophosphamide on embryonic development in the rabbit. Agents Actions2, 83–86.
32.
32. McClure, H.M., Wilk, A.L., Horigan, E.A., and Pratt, R.M. (1979). Induction of craniofacial malformations in rhesus monkeys (Macaca mulatta) with cyclophosphamide. Cleft Palate J. (16)3, 248–256.
33.
33. Greenburg, L.H., and Tanaka, K.R. (1964). Congenital anomalies probably induced by cyclophosphamide. JAMA188, 423–426.
34.
34. Gabriel-Robez, O., Rohmer, A., Clavert, J., and Schneegans, E. (1972). Teratogenic and lethal actions of diethylstilbestrol on the mouse embryo. Arch. Fr. Pediatr.29, 149–154.
35.
35. Nomura, T., and Masuda, M. (1980). Carcinogenic and teratogenic activities of diethylstilbestrol in mice. Life Sci.26, 1955–1962.
36.
36. McLachlan, J.A., Newbold, R.R., and Bullock, B.C. (1980). Reproductive tract lesions in male mice exposed prenatally to diethylstilbestrol. Science190, 991–992.
37.
37. McClachlan, J.A., Newbold, R.R., and Bullock, B.C. (1980). Long-term effects on the female mouse genital tract associated with prenatal exposure to diethylstilbestrol. Cancer Res.40, 3988–3999.
38.
38. Vorherr, H., Messer, R.H., Vorherr, U.F., Jordan, S.W., and Kornfield, M. (1979). Teratogenesis and carcinogenesis in rat offspring after transplacental and transmammary exposure to diethylstilbestrol. Biochem. Pharmacol.28, 1865–1877.
39.
39. Greene, R.R., Burrill, M.W., and Ivy, A.C. (1940). The effects of estrogens on the antenatal sexual development of the rat. Am. J. Anat.67, 305–345.
40.
40. Rustia, M., and Shubik, P. (1976). Transplacental effects of diethylstilbestrol on the genital tract of hamster offspring. Cancer Lett.1, 139–146.
41.
41. Hendrickx, A.G., Benirschke, K., Thompson, R.S., and Lucas, W.E. (1979). The effects of prenatal diethylstilbestrol (DES) exposure on the genitalia of pubertal Macaca mulatta. I. Female offspring. J. Reprod. Med.22, 233–240.
42.
42. Herbst, A.L., Poskanzer, D.C., Robboy, S.J., Friedlander, L., and Scully, R.E. (1975). Prenatal exposure to stilbestrol: A prospective comparison of exposed female offspring with unexposed controls. N. Engl. J. Med.292, 334–339.
43.
43. O'Brien, P.C., Noller, K.L., Robboy, S.J., Barnes, A.B., Kaufman, R.H., Tilley, B.C., and Townsend, D.E. (1979). Vaginal epithelial changes in young woman enrolled in the national cooperative diethylstilbestrol adenosis (DESAD) project. Obstst. Gynecol.53, 300–308.
44.
44. Harbison, R.D., and Becker, B.A. (1969). Relation of dosage and time of administration of diphenylhydantoin to its teratogenic effect in mice. Teratology2, 305–312.
45.
45. Martz, F., Failinger, C., Iii, and Blake, D.A. (1977). Phenytoin teratogenesis: Correlation between embryopathic effect and covalent binding of putative arene oxide metabolite in gestational tissue. J. Pharmacol. Exp. Ther.203, 231–239.
46.
46. Gabler, W.L. (1968). The effect of 5,5-diphenylhydantoin on the rat uterus and its fetuses. Arch. Int. Pharmacodyn.175, 141–152.
47.
47. McClain, R.M., and Langhoff, L. (1980). Teratogenicity of diphenylhydantoin in the New Zealand white rabbit. Teratology21, 371–379.
48.
48. Monson, R.R., Rosenberg, L., Hartz, S.C., Shapiro, S., Heinonen, O.P. and Slone, D. (1973). Diphenylhydantoin and selected congenital malformations. N. Engl. J. Med.289, 1049–1052.
49.
49. Hanson, J.W., and Smith, D.W. (1975). The fetal hydantoin syndrome. J. Pediatr.87, 285–290.
50.
50. Randall, C.L., and Taylor, W.J. (1979). Prenatal ethanol exposure in mice. Teratogenic effects. Teratology19, 305–312.
51.
51. Sandor, S., and Ameis, D. (1971). The action of aethanol on the prenatal development of albino rats. Rev. Roum. Embryol. Cytol. Ser. Embroyl.8, 105–118.
52.
52. Jones, K.L., and Smith, D.W. (1973). Recognition of the fetal alcohol syndrome in early infancy. Lancet2, 999–1001.
53.
53. Jones, K.L., Smith, D.W., and Ulleland, C.J. (1973). Pattern of malformation in offspring of chronic alcoholic mothers. Lancet1, 1267–1271.
54.
54. Ouellette, E.M., Rosett, H.L., Rosman, N.P., and Weiner, L. (1977). Adverse effects on offspring of maternal alcohol abuse during pregnancy. N. Engl. J. Med.297, 528–530.
55.
55. Hardin, B.D. (1983). Reproductive toxicity of the glycol ethers. Toxicology27(2), 91–102.
56.
56. Dagg, C.P. (1960). Sensitive stages for the production of developmental abnormalities in mice with 5-fluorouracil. Am. J. Anat.106, 89–96.
57.
57. Shah, R.M., and Mackay, R.A. (1978). Teratological evaluation of 5-fluorouracil and 5-bromo-2-deoxyuridine on hamster fetuses. J. Embryol. Exp. Morphol.43, 47–54.
58.
58. Wilson, J.G. (1971). Use of rhesus monkeys in teratological studies. Fed. Proc.30, 104–109.
59.
59. Stephens, J.D., Golbus, M.S., Miller, T.R., Wilber, R.R., and Epstein, C.J. (1980). Multiple congenital anomalies in a fetus exposed to 5-fluorouracil during the first trimester. Am. J. Obstet. Gynecol.137, 747–749.
60.
60. Kennedy, G.L., Smith, S.H., Keplinger, M.L., and Calandra, J.C. (1975). Evaluation of the teratological potential of hexachlorophene in rabbits and rats. Teratology12, 83–88.
61.
61. Kochar, D.M. (1975). Assessment of teratogenic response in cultured postimplantation mouse embryos: effects of hydroxyurea. In New Approaches to the Evaluation of Abnormal Embryonic Development. D. Neubert and H.J. Merker (eds.). Stuttgart: George Thieme, pp. 250–277.
62.
62. Butcher, R.E., Scott, W.J., Kazmaier, K., and Ritter, E.J. (1973). Postnatal effects in rats of prenatal treatment with hydroxyurea. Teratology7, 161–166.
63.
63. Chaube, S., and Murphy, M.L. (1966). The effects of hydroxyurea and related compounds on the rat fetus. Cancer Res.26, 1448–1457.
64.
64. Scott, W.J., Ritter, E.J., and Wilson, J.G., (1971). DNA synthesis inhibition and cell death associated with hydroxyurea teratogenesis in rat embryos. Dev. Biol.26, 306–315.
65.
65. DeSesso, J.M., and Jordan, R.L. (1977). Drug-induced limb dysplasia in fetal rabbits. Teratology15, 199–212.
66.
66. Ferm, V.H. (1965). Teratogenic activity of hydroxyurea. Lancet1, 1338–1339.
67.
67. Wilson, J.G., Scott, W.J., Ritter, E.J., and Fradkin, R. (1975). Comparative distribution and embryotoxicity of hydroxyurea in pregnant rats and rhesus monkeys. Teratology11, 169–178.
68.
68. Szabo, K.T. (1969). Teratogenicity of lithium in mice. Lancet2, 849.
69.
69. Schou, M., Goldfield, M.D., Weinstein, M.R., and Villeneuve, A. (1973). Lithium and pregnancy. 1. Report from the register of lithium babies. Br. Med. J.2, 135–136.
70.
70. Skalko, R.G., and Gold, M.P. (1974). Teratogenicity of methotrexate in mice. Teratology9, 159–164.
71.
71. Wilson, J.G., Scott, W.J., Ritter, E.J., and Fradkin, R. (1979). Comparative distribution and embryotoxicity of methotrexate in pregnant rats and rhesus monkeys. Teratology19, 71–80.
72.
72. Jordan, R.L., Wilson, J.G., and Schumacher, H.J. (1976). Embryotoxicity of the folate antagonist methotrexate in rats and rabbits. Teratology15, 73–80.
73.
73. Khera, K.S. (1976). Teratogenicity studies with methotrexate, aminopterin and acetylsalicylic acid in domestic cats. Teratology14, 21–28.
74.
74. Milunsky, A., Graef, J.W., and Gaynor, M.F. (1968). Methotrexate-induced congenital malformations with a review of the literature. J. Pediatr.72, 790–795.
75.
75. Tanaka, S., Kuwamura, T., Kawashima, K., Nakaura, S., Nagao, S., and Omori, Y. (1972). Effects of salicylic acid and acetylsalicylic acid on the fetuses and offspring of rats. Teratology6, 121.
76.
76. Sieber, S.M., Whang-Peng, J., Botkin, C., and Knutsen, T. (1978). Teratogenic and cytogenetic effects of some plant-derived antitumor agents (vincristine, colchicine, maytansine, VP-16–213 and VM-26) in mice. Teratology18, 31–48.
77.
77. Joneja, M., and Ungthavorn, S. (1969). Teratogenic effects of vincristine in three lines of mice. Teratology2, 235–240.
78.
78. Demyer, W. (1965). Cleft lip and jaw induced in fetal rats by vincristine. Arch. Anat. Pathol. (Paris)48, 181–186.
79.
79. Ferm, V.H. (1963). Congenital malformations in hamster embryos after treatment with vinblastine and vincristine. Science141, 426.
80.
80. Richards, I.D.G. (1972). A retrospective enquiry into possible teratogenic effects of drugs in pregnancy. In: Drugs and Fetal Development. M.A. Klingberg, A. Abramovici, and J. Chemke, (eds.). New York: Plenum Press, pp. 441–455.
